Abrocitinib and Prasugrel: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Prasugrel
Abrocitinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Prasugrel (Effient) is a blood thinner that stops your platelets from sticking together, which helps prevent clots but also makes bleeding more likely. Abrocitinib (Cibinqo) is a medicine for eczema that, especially in the first few months, can also raise your bleeding risk. When you take both together, those bleeding risks add up.
Because of this, using these two together during the first 3 months of abrocitinib is not recommended. The good news is your care team can manage this by choosing a safer plan for you. Please don't stop or change either medicine on your own. Talk with your doctor or pharmacist so they can sort out the best option.
Interaction: Additive impairment of hemostasis. Prasugrel is an irreversible P2Y12 antiplatelet agent (a prodrug activated hepatically); abrocitinib, a JAK1 inhibitor, carries early bleeding/thrombocytopenia risk. The concern is pharmacodynamic (additive), not a PK/enzyme effect.
- Direction: Increased bleeding risk.
- Severity: Contraindicated per labeling during the first 3 months of abrocitinib therapy for antiplatelet agents other than low-dose aspirin (
What happens
Increased risk of bleeding
Interaction Deep Dive
Giving abrocitinib together with antiplatelet drugs is contraindicated throughout the initial 3 months of therapy, because doing so raises the likelihood of bleeding; low-dose aspirin (81 mg per day or below) is the one exception to this restriction1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
This combination is flagged as one to avoid during the first 3 months of abrocitinib, so the most important step is to let your care team make the plan.
- Keep taking both as prescribed until you speak with your doctor or pharmacist. Do not stop either one on your own.
- Your team may choose an alternative or adjust timing, since antiplatelet agents other than low-dose aspirin (81 mg/day or less) are not recommended with abrocitinib early on.
- Watch for signs of bleeding: unusual bruising, nosebleeds, blood in urine or stool, black stools, or bleeding that won't stop.
- Tell any provider you take both medicines.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Abrocitinib and Prasugrel together?
Combining prasugrel with abrocitinib raises bleeding risk and is not recommended during the first 3 months of abrocitinib, so contact your doctor or pharmacist before taking them together. Do not stop either medicine on your own. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abrocitinib and Prasugrel interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Abrocitinib and Prasugrel interaction managed?
This combination is flagged as one to avoid during the first 3 months of abrocitinib, so the most important step is to let your care team make the plan. Keep taking both as prescribed until you speak with your doctor or pharmacist. Do not stop either one on your own. Your team may choose an alternative or adjust timing, since antiplatelet agents other than low-dose aspirin (81 mg/day or less) are… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Abrocitinib or Prasugrel need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: CIBINQO(TM) oral tablets, abrocitinib oral tablets. Pfizer Labs (per FDA), New York, NY, 2022. DailyMed
Keep reading about Prasugrel
Keep reading about Abrocitinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist